Marc Banjak
Fortune : 31 750 $ au 31/08/2026
Fortune : 31 750 $ au 31/08/2026
Mr. Marc A. Banjak is a Chief Legal Officer at iBio, Inc. Mr. Banjak was previously employed as a General Counsel by Dova Pharmaceuticals, Inc., a General Counsel by Istari Oncology, Inc., and a Member by The Colorado Bar Association.
He received his undergraduate degree from Franklin & Marshall College and a graduate degree from Sturm College of Law.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IBIO, INC. 0,07 % | 01/09/2026 | 25 000 ( 0,07 % ) | 31 750 $ | 31/08/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| IBIO, INC. | Conseiller Juridique Général | - |
| Sociétés | Poste | Fin |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Conseiller Juridique Général | 01/04/2021 |
The Colorado Bar Association | Corporate Officer/Principal | - |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Comptroller/Controller/Auditor | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 6 |
|---|---|
Franklin & Marshall College
Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Colorado Bar Association | |
iBio, Inc.
iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins | Health Technology |
Sturm College of Law
Sturm College of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs with disorder of low blood platelet count | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national